Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis
Cochrane Database of Systematic Reviews2007Vol. 7(1), pp. CD005160–CD005160
Citations Over TimeTop 10% of 2007 papers
Abstract
Presently, there are insufficient data to support or refute the use of ursodeoxycholic acid for patients with non-alcoholic fatty liver or steatohepatitis. It may be advisable to carry out large randomised clinical trials on this topic.
Related Papers
- → Metabolic and histological features of non‐alcoholic fatty liver disease patients with different serum alanine aminotransferase levels(2008)125 cited
- → PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic and Alcoholic Fatty Liver Diseases: Evidence From Meta-analysis(2015)3 cited
- → Correlation of serum aspartate aminotransferase level to platelet count ratio index with non-alcoholic fatty liver disease activity score(2019)2 cited
- → Non-alcoholic fatty liver disease: a heterogeneous phenotype. Pleiotropic effects of ursodeoxycholic acid(2023)1 cited
- The Efficacy of Ursodeoxycholic Acid in the Treatment of Non-alcoholic Steatohepatitis: A 15-year Systematic Review(2020)